ReviewFrontiers in pharmacology2016
Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Engineering nanoallergens to investigate origins of immunogenicity and cross-reactivity in cephalosporin allergy.The Journal of allergy and clinical immunology · 2025Article
- Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions.Frontiers in pharmacology · 2025Review
- Clues of HLAs, metabolic SNPs, and epigenetic factors in T cell-mediated drug hypersensitivity reactions.Heliyon · 2024Review
- Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis.Toxicological sciences : an official journal of the Society of Toxicology · 2024Review
- Nimesulide-Induced Fixed Drug Eruption Followed by Etoricoxib-Induced Fixed Drug Eruption: An Unusual Case Report and Review of the Literature.Journal of clinical medicine · 2024Review
- Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy.Biosensors · 2023Review
- Pharmacogenomic profile of a central European urban random population-Czech population.PloS one · 2023Observational
- The Immunogenetics of Cutaneous Drug Reactions.Advances in experimental medicine and biology · 2022Article
- Pharmacogenetic information in Swiss drug labels - a systematic analysis.The pharmacogenomics journal · 2021Article
- Preparation and Evaluation of Lipid Emulsion Containing 13 Vitamins for Injection Without Anaphylactoid Reactions.International journal of nanomedicine · 2021Article
- Genome-wide Study Identifies Association between HLA-BAmerican journal of human genetics · 2020Article
- Drug Allergy Profile From a National Drug Allergy Registry.Frontiers in pharmacology · 2020Article
- Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.Scientific reports · 2019Article
- In Reply.Deutsches Arzteblatt international · 2018Article
- Drug Hypersensitivity.Deutsches Arzteblatt international · 2018Review
- Sulfonamide Drug Allergy.Current allergy and asthma reports · 2018Review
- Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus.Clinical pharmacology and therapeutics · 2018Article
- Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review.Current problems in pediatric and adolescent health care · 2018Review
- Comparison of Quantitative and Qualitative (Q)SAR Models Created for the Prediction of KFrontiers in pharmacology · 2018Article
- Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database.European journal of clinical pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions adverse drug reaction (ADR) occur in approximately 17% of patients. Avoiding ADR is thus mandatory from both an ethical and an economic point of view. Whereas, pharmacogenetics changes of the pharmacokinetics may contribute to the explanation of some type A reactions, strong relationships of genetic markers has also been shown for drug hypersensitivity belonging to type B reactions. We present the classifications of ADR, discuss genetic influences and focus on delayed-onset hypersensitivity reactions, i.e., drug-induced liver injury, drug-induced agranulocytosis, and severe cutaneous ADR. A guidance how to read and interpret the contingency table is provided as well as an algorithm whether and how a test for a pharmacogenetic biomarker should be conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.